4.3 Review

Management of Hepatocellular Carcinoma: Current Status and Future Directions

期刊

GUT AND LIVER
卷 9, 期 4, 页码 437-448

出版社

EDITORIAL OFFICE GUT & LIVER
DOI: 10.5009/gnl15022

关键词

Carcinoma, hepatocellular; Transarterial chemoembolization; Radiofrequency ablation; Staging systems; Sorafenib

向作者/读者索取更多资源

Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide. This cancer commonly arises against a background of chronic liver disease. As a result, a patient with HCC requires multidisciplinary care. Treatment options vary widely based on tumor burden and metastases. The most widely utilized staging system. is the Barcelona Clinic Liver Cancer staging system, which recommends treatments based on tumor size and the underlying liver disease and functional status of the patient Treatment options range from surgical resection or transplantation to locoregional therapies with modalities such as radiofrequency ablation and transarterial chemoembolization to systemic chemotherapies. Future care involves the development of combination therapies that afford the best tumor response, further clarification of the patients best suited for therapies and the development of new oral chemotherapeutic agents.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据